Supplementary Agreement to Stock Transfer Agreement among Xiuzheng Pharmaceutical Group, Harbin Humankind Biology Technology, Xin Sun, and Harbin Huimeijia Medicine Company
This agreement, dated October 12, 2016, is between Xiuzheng Pharmaceutical Group, Harbin Humankind Biology Technology, Xin Sun, and Harbin Huimeijia Medicine Company. The parties agree to rescind a previous supplementary agreement from February 9, 2015, and proceed with the transfer of core assets according to the original stock transfer agreement signed on December 24, 2014. Each party will hold a signed copy, and the agreement is effective upon signing.
Supplementary Agreement
Party A: Xiuzheng Pharmaceutical Group Co., Ltd
Party B: Harbin Humankind Biology Technology Co., Limited
Party C: Xin Sun
Party D: Harbin Huimeijia Medicine Company
On December 24, 2014, Party A, Party B, Party C, and Party D (the “Four Parties”) entered into a stock transfer agreement (the “Stock Transfer Agreement”) and on February 9, 2015, the Four Parties entered into a supplementary agreement (the “2015 Supplementary Agreement”). In order to accelerate the transfer of core assets, the Four Parties entered into the following terms after friendly negotiation.
I. The Four Parties agreed to rescind the 2015 Supplementary Agreement signed on February 9, 2015.
II. The Four Parties agreed to execute the transfer based on the Stock Transfer Agreement signed on December 24, 2014.
III. This Agreement is executed in four copies. Each party holds one copy. This Agreement is taken into effect after the undersigned sign or seal on the Agreement.
1
Party A: Xiuzheng Pharmaceutical Group Co., Ltd (seal)
/s/ Jianzhong Wang (corporate seal affixed)
Date: October 12, 2016
Party B: Harbin Humankind Biology Technology Co., Limited (seal)
(corporate seal affixed)
Date: October 12, 2016
Party C: Xin Sun
/s/ Xin Sun
Date: October 12, 2016
Party D: Harbin Huimeijia Medicine Company (seal)
(corporate seal affixed)
Date: October 12, 2016
2
